Skip to main content
Dishman Carbogen Amcis Limited logo

Dishman Carbogen Amcis Limited — Investor Relations & Filings

Ticker · DCAL ISIN · INE385W01011 LEI · 335800KM9GDZE9W21C94 BSE.NS Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IN India
Listing BSE.NS DCAL

About Dishman Carbogen Amcis Limited

https://imdcal.com/

Dishman Carbogen Amcis Limited is a global contract development and manufacturing organization providing integrated services for the development and manufacture of active pharmaceutical ingredients. The company specializes in high potency APIs, offering a comprehensive range of services from process research and development to commercial-scale production. Its portfolio includes vitamin D and its analogs, cholesterol, and specialty chemicals. The organization supports drug development cycles with technical expertise in complex chemistry and niche technologies, operating through a network of facilities across multiple continents. Additionally, the company provides disinfectant products and services for various industrial applications, maintaining a focus on technical innovation and quality standards throughout the product lifecycle.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings Classification · 90% confidence The document is a statutory listing regulation disclosure under SEBI LODR: the outcome of the Board meeting, audited financial results for the quarter and year ended March 31, 2026, along with statutory auditor’s report and related certificates. It is not a full Annual Report, proxy or investor presentation but rather a regulatory announcement filed with the stock exchanges, containing condensed financial results and approvals. Therefore it is classified as a general regulatory filing.
2026-05-19 English
Appointment
Regulatory Filings
2026-05-19 English
PFA.
Regulatory Filings Classification · 85% confidence The document is an official stock‐exchange filing informing investors of the outcome of a Board meeting under SEBI LODR regulations. It discloses audited financial results, auditor appointment, borrowing approvals, etc., but is not the full Annual Report (10‐K), a standalone Audit Report (AR), or a simple Earnings Release (ER). It is a regulatory compliance announcement and thus best fits the catch‐all Regulatory Filings category.
2026-05-19 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is a disclosure under SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 informing exchanges of the Board meeting outcome, including the audited financial results (standalone and consolidated) for the quarter and year ended 31 March 2026, accompanied by the statutory auditors’ report. It provides full financial statements rather than just highlights, and is not a full annual report (10-K) but a statutory quarterly/period announcement with substantive financial data. This matches the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-19 English
Outcome of Board Meeting held on 19th May, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is a statutory listing disclosure under SEBI LODR (Regulation 33/52) outlining the Board’s approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31 March 2026, includes actual financial statements and auditor’s report, and is filed as part of the quarterly/annual results process. It is not a full Annual Report (10-K), nor merely an announcement of a report (RPA/RNS), but a comprehensive interim/quarterly report containing substantive financial data. Therefore, it best fits the Interim/Quarterly Report category. FY 2026
2026-05-19 English
Outcome of Board Meeting
Regulatory Filings Classification · 87% confidence The document is clearly an exchange filing under SEBI’s LODR framework conveying the outcome of a Board meeting – approval of audited quarterly and full‐year financial results, statutory auditor reappointment, ECB proposal and borrowing limit increase – rather than a full Annual Report (10-K) or interim/quarterly report (IR) containing management discussion or a standalone audit report (AR). It is not merely a brief announcement of a report’s publication (RPA) nor an investor presentation (IP), earnings release highlights (ER), or proxy/materials for an AGM (PSI/AGM-R). Therefore it falls under general regulatory/compliance disclosure as a Regulatory Filing (RNS).
2026-05-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.